A critical review of the diagnosis and management of Barrett's esophagus: The AGA Chicago Workshop

Prateek Sharma, Kenneth McQuaid, John Dent, M. Brian Fennerty, Richard Sampliner, Stuart Spechler, Alan Cameron, Douglas Corley, Gary Falk, John Goldblum, John Hunter, Janusz Jankowski, Lars Lundell, Brian Reid, Nicholas J. Shaheen, Amnon Sonnenberg, Kenneth Wang, Wilfred Weinstein

Research output: Contribution to journalArticle

448 Citations (Scopus)

Abstract

Background & Aims: The diagnosis and management of Barrett's esophagus (BE) are controversial. We conducted a critical review of the literature in BE to provide guidance on clinically relevant issues. Methods: A multidisciplinary group of 18 participants evaluated the strength and the grade of evidence for 42 statements pertaining to the diagnosis, screening, surveillance, and treatment of BE. Each member anonymously voted to accept or reject statements based on the strength of evidence and his own expert opinion. Results: There was strong consensus on most statements for acceptance or rejection. Members rejected statements that screening for BE has been shown to improve mortality from adenocarcinoma or to be cost-effective. Contrary to published clinical guidelines, they did not feel that screening should be recommended for adults over age 50, regardless of age or duration of heartburn. Members were divided on whether surveillance prolongs survival, although the majority agreed that it detects curable neoplasia and can be cost-effective in selected patients. The majority did not feel that acid-reduction therapy reduces the risk of esophageal adenocarcinoma but did agree that nonsteroidal antiinflammatory drugs are associated with a cancer risk reduction and are of promising (but unproven) value. Participants rejected the notion that mucosal ablation with acid suppression prevents adenocarcinoma in BE but agreed that this may be an appropriate strategy in a subgroup of patients with high-grade dysplasia. Conclusions: Based on this review of BE, the opinions of workshop members on issues pertaining to screening and surveillance are at variance with published clinical guidelines.

Original languageEnglish (US)
Pages (from-to)310-330
Number of pages21
JournalGastroenterology
Volume127
Issue number1
DOIs
StatePublished - Jul 2004

Fingerprint

Barrett Esophagus
Education
Adenocarcinoma
Guidelines
Costs and Cost Analysis
Heartburn
Acids
Expert Testimony
Risk Reduction Behavior
Neoplasms
Consensus
Anti-Inflammatory Agents
Survival
Mortality
Therapeutics
Pharmaceutical Preparations

Keywords

  • AB
  • Alcian blue
  • Barrett's esophagus
  • BE
  • CK
  • cytokeratin
  • gastroesophageal junction
  • GEJ
  • long-segment BE
  • LSBE
  • PPI
  • proton pump inhibitor
  • short-segment BE
  • SSBE

ASJC Scopus subject areas

  • Gastroenterology

Cite this

A critical review of the diagnosis and management of Barrett's esophagus : The AGA Chicago Workshop. / Sharma, Prateek; McQuaid, Kenneth; Dent, John; Fennerty, M. Brian; Sampliner, Richard; Spechler, Stuart; Cameron, Alan; Corley, Douglas; Falk, Gary; Goldblum, John; Hunter, John; Jankowski, Janusz; Lundell, Lars; Reid, Brian; Shaheen, Nicholas J.; Sonnenberg, Amnon; Wang, Kenneth; Weinstein, Wilfred.

In: Gastroenterology, Vol. 127, No. 1, 07.2004, p. 310-330.

Research output: Contribution to journalArticle

Sharma, P, McQuaid, K, Dent, J, Fennerty, MB, Sampliner, R, Spechler, S, Cameron, A, Corley, D, Falk, G, Goldblum, J, Hunter, J, Jankowski, J, Lundell, L, Reid, B, Shaheen, NJ, Sonnenberg, A, Wang, K & Weinstein, W 2004, 'A critical review of the diagnosis and management of Barrett's esophagus: The AGA Chicago Workshop', Gastroenterology, vol. 127, no. 1, pp. 310-330. https://doi.org/10.1053/j.gastro.2004.04.010
Sharma, Prateek ; McQuaid, Kenneth ; Dent, John ; Fennerty, M. Brian ; Sampliner, Richard ; Spechler, Stuart ; Cameron, Alan ; Corley, Douglas ; Falk, Gary ; Goldblum, John ; Hunter, John ; Jankowski, Janusz ; Lundell, Lars ; Reid, Brian ; Shaheen, Nicholas J. ; Sonnenberg, Amnon ; Wang, Kenneth ; Weinstein, Wilfred. / A critical review of the diagnosis and management of Barrett's esophagus : The AGA Chicago Workshop. In: Gastroenterology. 2004 ; Vol. 127, No. 1. pp. 310-330.
@article{b696e5a925104fee9d23e5587ab0a576,
title = "A critical review of the diagnosis and management of Barrett's esophagus: The AGA Chicago Workshop",
abstract = "Background & Aims: The diagnosis and management of Barrett's esophagus (BE) are controversial. We conducted a critical review of the literature in BE to provide guidance on clinically relevant issues. Methods: A multidisciplinary group of 18 participants evaluated the strength and the grade of evidence for 42 statements pertaining to the diagnosis, screening, surveillance, and treatment of BE. Each member anonymously voted to accept or reject statements based on the strength of evidence and his own expert opinion. Results: There was strong consensus on most statements for acceptance or rejection. Members rejected statements that screening for BE has been shown to improve mortality from adenocarcinoma or to be cost-effective. Contrary to published clinical guidelines, they did not feel that screening should be recommended for adults over age 50, regardless of age or duration of heartburn. Members were divided on whether surveillance prolongs survival, although the majority agreed that it detects curable neoplasia and can be cost-effective in selected patients. The majority did not feel that acid-reduction therapy reduces the risk of esophageal adenocarcinoma but did agree that nonsteroidal antiinflammatory drugs are associated with a cancer risk reduction and are of promising (but unproven) value. Participants rejected the notion that mucosal ablation with acid suppression prevents adenocarcinoma in BE but agreed that this may be an appropriate strategy in a subgroup of patients with high-grade dysplasia. Conclusions: Based on this review of BE, the opinions of workshop members on issues pertaining to screening and surveillance are at variance with published clinical guidelines.",
keywords = "AB, Alcian blue, Barrett's esophagus, BE, CK, cytokeratin, gastroesophageal junction, GEJ, long-segment BE, LSBE, PPI, proton pump inhibitor, short-segment BE, SSBE",
author = "Prateek Sharma and Kenneth McQuaid and John Dent and Fennerty, {M. Brian} and Richard Sampliner and Stuart Spechler and Alan Cameron and Douglas Corley and Gary Falk and John Goldblum and John Hunter and Janusz Jankowski and Lars Lundell and Brian Reid and Shaheen, {Nicholas J.} and Amnon Sonnenberg and Kenneth Wang and Wilfred Weinstein",
year = "2004",
month = "7",
doi = "10.1053/j.gastro.2004.04.010",
language = "English (US)",
volume = "127",
pages = "310--330",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - A critical review of the diagnosis and management of Barrett's esophagus

T2 - The AGA Chicago Workshop

AU - Sharma, Prateek

AU - McQuaid, Kenneth

AU - Dent, John

AU - Fennerty, M. Brian

AU - Sampliner, Richard

AU - Spechler, Stuart

AU - Cameron, Alan

AU - Corley, Douglas

AU - Falk, Gary

AU - Goldblum, John

AU - Hunter, John

AU - Jankowski, Janusz

AU - Lundell, Lars

AU - Reid, Brian

AU - Shaheen, Nicholas J.

AU - Sonnenberg, Amnon

AU - Wang, Kenneth

AU - Weinstein, Wilfred

PY - 2004/7

Y1 - 2004/7

N2 - Background & Aims: The diagnosis and management of Barrett's esophagus (BE) are controversial. We conducted a critical review of the literature in BE to provide guidance on clinically relevant issues. Methods: A multidisciplinary group of 18 participants evaluated the strength and the grade of evidence for 42 statements pertaining to the diagnosis, screening, surveillance, and treatment of BE. Each member anonymously voted to accept or reject statements based on the strength of evidence and his own expert opinion. Results: There was strong consensus on most statements for acceptance or rejection. Members rejected statements that screening for BE has been shown to improve mortality from adenocarcinoma or to be cost-effective. Contrary to published clinical guidelines, they did not feel that screening should be recommended for adults over age 50, regardless of age or duration of heartburn. Members were divided on whether surveillance prolongs survival, although the majority agreed that it detects curable neoplasia and can be cost-effective in selected patients. The majority did not feel that acid-reduction therapy reduces the risk of esophageal adenocarcinoma but did agree that nonsteroidal antiinflammatory drugs are associated with a cancer risk reduction and are of promising (but unproven) value. Participants rejected the notion that mucosal ablation with acid suppression prevents adenocarcinoma in BE but agreed that this may be an appropriate strategy in a subgroup of patients with high-grade dysplasia. Conclusions: Based on this review of BE, the opinions of workshop members on issues pertaining to screening and surveillance are at variance with published clinical guidelines.

AB - Background & Aims: The diagnosis and management of Barrett's esophagus (BE) are controversial. We conducted a critical review of the literature in BE to provide guidance on clinically relevant issues. Methods: A multidisciplinary group of 18 participants evaluated the strength and the grade of evidence for 42 statements pertaining to the diagnosis, screening, surveillance, and treatment of BE. Each member anonymously voted to accept or reject statements based on the strength of evidence and his own expert opinion. Results: There was strong consensus on most statements for acceptance or rejection. Members rejected statements that screening for BE has been shown to improve mortality from adenocarcinoma or to be cost-effective. Contrary to published clinical guidelines, they did not feel that screening should be recommended for adults over age 50, regardless of age or duration of heartburn. Members were divided on whether surveillance prolongs survival, although the majority agreed that it detects curable neoplasia and can be cost-effective in selected patients. The majority did not feel that acid-reduction therapy reduces the risk of esophageal adenocarcinoma but did agree that nonsteroidal antiinflammatory drugs are associated with a cancer risk reduction and are of promising (but unproven) value. Participants rejected the notion that mucosal ablation with acid suppression prevents adenocarcinoma in BE but agreed that this may be an appropriate strategy in a subgroup of patients with high-grade dysplasia. Conclusions: Based on this review of BE, the opinions of workshop members on issues pertaining to screening and surveillance are at variance with published clinical guidelines.

KW - AB

KW - Alcian blue

KW - Barrett's esophagus

KW - BE

KW - CK

KW - cytokeratin

KW - gastroesophageal junction

KW - GEJ

KW - long-segment BE

KW - LSBE

KW - PPI

KW - proton pump inhibitor

KW - short-segment BE

KW - SSBE

UR - http://www.scopus.com/inward/record.url?scp=3242658404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242658404&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2004.04.010

DO - 10.1053/j.gastro.2004.04.010

M3 - Article

C2 - 15236196

AN - SCOPUS:3242658404

VL - 127

SP - 310

EP - 330

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 1

ER -